DETAILED ACTION
Notice of AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election of Group II, claims 46, 49 and 52 in the reply filed on 17 August 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
The requirement is deemed proper and therefore made Final.
Status of Application
Claims 1-2, 4, 6-8, 10-11, 14-15, 17, 20, 23, 26-27, 40-41, 46, 49 and 52 are pending; Claims 1-2, 4, 6-8, 10-11, 14-15, 17, 20, 23, 26-27, 40-41 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter, there being no allowable generic or linking claim. Thus, claims 46, 49 and 52 are subject to examination on the merits.
Priority
The instant application is a 371 of PCT/US2023/063477 filed 01 March 2023 which claims benefit of US provisional application 63315631 filed 02 March 2022 is acknowledged.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 29 August 2024 has been considered by the examiner. See initialed and signed PTO/SB/08.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 46, 49 and 52 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
The claims are drawn to methods of increasing T-cell activation, increasing the production of short chain fatty acids (SCFAs) and increasing the amount of bacteria of the genus Bifidobacterium or Lactobacillus in subjects. However, any asserted improvement in/for anything needs a comparative. That is, increased compared to what (e.g. compared to the levels prior to the administration of the composition)?
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 46, 49 and 52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Houssain (US 2020/0390867 – cited on IDS).
Houssain teaches:
Administering Revivify composition, which comprises the following in a gel composition (See Table 1):
Revivify Anti - Oxidant Composition
17.88 g/30 ml
SI. #
Proprietary Blend 17.88 g
QTY/mg
1
Soluble corn fiber (Fibersol-2)
4000
2
Pomegranate Juice Concentrate
4000
3
Concord Grape Juice Concentrate
4000
4
Blueberry Juice Concentrate
2000
5
Dark Sweet Cherry Juice Concentrate
1450
6
Sour Cherry Juice Concentrate
1450
7
Goji Pulp
294
8
Acai Concentrate Juice
200
9
Alobira Juice
200
10
Green Tea
200
11
Resveratrol
80
12
Extramel SOD (14000 unit/g)
6
17880
13
CMC
60.5
14
Xanthan
60.5
15
QS Water (30 ml)
Thus, the composition comprises 4000mg of soluble corn fiber and 84 U of superoxide dismutase (SOD) (e.g. 14000 Unit/g and the composition comprising 6 mg (.006g) is calculated as: 14000U/g x .006g = 84 Units).
Said composition is orally administered to various human patients suffering from a wide-variety of ailments such as: COVID-19, diabetes, Myasthenia Gravis, MS, Gout, Viral symptoms. – See Examples 4-9. Thus, inherently, the patients being administered the liquid gel formulation comprising 4000 mg of soluble corn fiber and 84 U of SOD (among other things) will necessarily have increased T-cell activation, increased SFCA’s and increased Bifidobacterium or Lactobacillus in the digestive track, even if Houssain was not aware of this feature at the time of administering the composition to the different patient/subject populations (MPEP 2112(II)).
Thus, the teachings of Hossain inherently anticipate claims 46, 49 and/or 52.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUZANNE M NOAKES whose telephone number is (571)272-2924. The examiner can normally be reached M-F (7-4).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Manjunath Rao can be reached at 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUZANNE M NOAKES/Primary Examiner, Art Unit 1656 21 October 2026